Search for: "Anda Inc." Results 161 - 180 of 963
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Chief Judge Stark Denies Prevailing Party’s Motion for Attorneys’ Fees and Expenses in ANDA Action
22 Oct 2017, 11:16 am by Gregory B. Williams
ICON Healthy & Fitness, Inc., 134 S. [read post]
Delaware Intellectual Property Litigation - http://delawareintellectualproperty.foxrothschild.com/
Judge Andrews Finds Plaintiff Proved Infringement of Asserted Claims of Patents-in-Suit Following Three-Day Bench Trial in Hatch-Waxman Action
14 Oct 2017, 5:19 am by Gregory B. Williams
Andrews in Orexigen Therapeutics, Inc. v. [read post]
Delaware Intellectual Property Litigation - http://delawareintellectualproperty.foxrothschild.com/
ED Wisc discusses "a sandbox for gratuitous sniping" in case about lithium-ion batteries used in power tools
23 Sep 2017, 12:39 pm by Lawrence B. Ebert
Inc. v. [read post]
IPBiz - http://ipbiz.blogspot.com/
What are “Acts of Infringement” and Where is “A Regular and Established Place of Business” for a Hatch-Waxman Defendant: The District of Delaware Weighs in on the Patent Venue Rule
20 Sep 2017, 9:18 am by Christine A. Gaddis
In the face of this conundrum, the court relied on the Federal Circuit’s recent decision in Acorda Therapeutics Inc. v. [read post]
IP Law Alert - http://www.iplawalert.com
Frequent ANDA Filer May Have Regular and Established Place of Business in Delaware​
13 Sep 2017, 7:44 am by Docket Navigator
Mylan Pharmaceuticals, Inc., 1-17-cv-00379 (DED September 11, 2017, Order) (Stark, USDJ) [read post]
Docket Report Patent Infringement Blog - http://docketreport.blogspot.com/
Millennium Pharmaceuticals, Inc. v. Sandoz Inc. (Fed. Cir. 2017)
18 Jul 2017, 9:58 pm by Patent Docs
Noonan -- In multiple ANDA litigations against multiple defendants, Millennium Pharmaceuticals, Inc. had several of its asserted claims held invalid for obviousness at the district court. [read post]
Patent Docs - http://www.patentdocs.org/
¿Será verdad lo que leerán?
12 Jul 2017, 4:20 am by José Guillermo
Buscan manipular, malograr, ensuciar a quienes han podido aceptar sus propias realidades y tienen la valentía de exponerla buscando también el apoyo legal para no ser masacrados por los "rectos" que creen que matando a sus víctimas podrán mantener su fachada de pureza incólume. [read post]
Nuevo Código Procesal Penal - Una Lectura Fácil - http://www.joseguianderson.blogspot.com/
Chief Judge Stark Denies Defendants’ Motion for Reargument of Court’s Order Holding Defendants Liable for Costs of ANDA Litigation Going Forward Under Certain Conditions
24 Jun 2017, 1:16 pm by Gregory B. Williams
Stark in UCB, Inc., et al. v. [read post]
Delaware Intellectual Property Litigation - http://delawareintellectualproperty.foxrothschild.com/
Filing Patents Does Not Create Jurisdiction Outside of the E.D. Virginia
24 May 2017, 4:32 am by R. David Donoghue
Daiichi Sankyo, Inc., No. 16 C 2988, 3956 & 4876, Slip Op. [read post]
Chicago IP Litigation Blog - http://www.chicagoiplitigation.com/
Braintree Laboratories, Inc. v. Breckenridge Pharmaceutical, Inc. (Fed. Cir. 2017)
8 May 2017, 8:27 pm by Patent Docs
Noonan -- The Federal Circuit's decision on Friday, in Braintree Laboratories, Inc. v. [read post]
Patent Docs - http://www.patentdocs.org/
CAFC tackles colon cleansing and purgation; Braintree wins its appeal
6 May 2017, 10:11 am by Lawrence B. Ebert
"Braintree Laboratories, Inc. [read post]
IPBiz - http://ipbiz.blogspot.com/
Federal Circuit Holds Non-Public Sales Can Still Satisfy the On-Sale Bar for Patents under the AIA
4 May 2017, 8:26 am by Eric Caligiuri
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
IP Law Blog - http://www.theiplawblog.com/
Federal Circuit Holds Non-Public Sales Can Still Satisfy the On-Sale Bar for Patents under the AIA
4 May 2017, 8:26 am by Eric Caligiuri
(“Helsinn”) brought suit against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd. [read post]
IP Law Blog - http://www.theiplawblog.com/
CAFC in Helsinn v. Teva. AIA did NOT change meaning of "on sale." Invention can be ready for patenting before FDA approval.
1 May 2017, 10:58 am by Lawrence B. Ebert
(collectively, “Teva”) alleging that the filing of Teva’sAbbreviated New Drug Application (“ANDA”) constitutedan infringement of various claims of those patents. [read post]
IPBiz - http://ipbiz.blogspot.com/
Meritless Claim for Declaration of ANDA Infringement by Possible Future Drug Formulation Justifies Award of Attorney Fees under 35 U.S.C. § 285​
26 Apr 2017, 7:24 am by Docket Navigator
Luitpold Pharmaceuticals, Inc. et al, 2-16-cv-02290 (NJD April 24, 2017, Order) (Walls, USDJ) [read post]
Docket Report Patent Infringement Blog - http://docketreport.blogspot.com/
Wrongful dismissal – when does the limitation period clock start running?
19 Apr 2017, 6:56 am by Andrew Vey
But as the case of Bailey v Milo-Food & Agricultural Infrastructure & Services Inc. (2017 ONSC 1789) reminds us, complications can arise when a worker is dismissed by means of working notice.Bailey had worked for Mio-Food for nearly 41 years prior to being informed of his dismissal. [read post]
Ottawa Employment & Labour Law Blog - http://www.vwlawyers.ca/blog/
More on The Medicines Company v. Mylan, 2017 U.S. App. LEXIS 5947. Reverse doctrine of equivalents?
18 Apr 2017, 6:52 am by Lawrence B. Ebert
., Inc. v. [read post]
IPBiz - http://ipbiz.blogspot.com/
Bristol-Myers Squibb, Pfizer file ANDA lawsuits against makers of generic Eliquis
12 Apr 2017, 10:15 am by Steve Brachmann
(NYSE:BMY) and Pfizer, Inc. [read post]
IPWatchdog - http://www.ipwatchdog.com/
The Medicines Company v. Mylan, Inc. (Fed. Cir. 2017)
9 Apr 2017, 9:59 pm by Patent Docs
Noonan -- The Federal Circuit returned to its consideration of the outcome in the District Court of The Medicines Company's ANDA litigation against Mylan and Bioniche Pharma over a proposed generic version of Medicines' bivalirudin drug (sold as Angiomax®), an anticoagulant used in heart surgery. [read post]
Patent Docs - http://www.patentdocs.org/
CAFC in Medicines v. Mylan. Claim term limited to the sole portion of the specification that adequately discloses term
6 Apr 2017, 1:35 pm by Lawrence B. Ebert
In response to an AbbreviatedNew Drug Application (“ANDA”) submitted by Mylan,Inc. [read post]
IPBiz - http://ipbiz.blogspot.com/